ArticleJournal of hepatology2021
Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score.Updates in surgery · 2021Pooled it
- The Potential of Artificial Intelligence to Improve Selection Criteria for Liver Transplantation in HCC.Cancers · 2025Review
- Article
- Liver transplantation for HCC within and beyond Milan Criteria: single center experience with literature review.Frontiers in surgery · 2025Article
- How to Predict Recurrence After Resection of Hepatocellular Carcinoma.Anticancer research · 2025Article
- DCP as a biomarker for TACE efficacy in hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Combining a deep learning model with clinical data better predicts hepatocellular carcinoma behavior following surgery.Journal of pathology informatics · 2024Article
- mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.Molecular biomedicine · 2024Article
- Trends in Survival for Adult Organ Transplantation.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024Article
- Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2023Article
- Cumulative exposure to tacrolimus during early period after liver transplantation does not affect the recurrence of hepatocellular carcinoma.Scientific reports · 2023Article
- Article
- Estimating Microvascular Invasion in Patients with Resectable Multinodular Hepatocellular Carcinoma by Using Preoperative Contrast-Enhanced MRI: Establishment and Validation of a Risk Score.Journal of hepatocellular carcinoma · 2023Article
- Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma.Annals of gastroenterological surgery · 2023Review
- Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.Clinical and molecular hepatology · 2022Review
- Accurate long-term prediction of death for patients with cirrhosis.Hepatology (Baltimore, Md.) · 2022Article
- Blockchain and artificial intelligence technology in e-Health.Environmental science and pollution research international · 2021Review
- Liver transplantation in malignant disease.World journal of clinical oncology · 2021Review
- Prognostic risk scores for liver transplantation: game changers or statistical artworks?Hepatobiliary surgery and nutrition · 2021Article
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsLiver transplant priority in the US and Europe follows the 'sickest-first' principle. However, for patients with hepatocellular carcinoma (HCC), priority is based on binary tumor criteria to expedite transplant for patients with 'acceptable' post-transplant outcomes. Newer risk scores developed to overcome limitations of these binary criteria are insufficient to be used for waitlist priority as they focus solely on HCC-related pre-transplant variables. We sought to develop a risk score to predict post-transplant survival for patients using HCC- and non-HCC-related variables.
methodsWe performed a retrospective cohort study using national registry data on adult deceased-donor liver transplant (DDLT) recipients with HCC from 2/27/02-12/31/18. We fit Cox regression models focused on 5- and 10-year survival to estimate beta coefficients for a risk score using manual variable selection. We then calculated absolute predicted survival time and compared it to available risk scores.
resultsAmong 6,502 adult DDLT recipients with HCC, 11 variables were selected in the final model. The AUCs at 5- and 10-years were: 0.62, 95% CI 0.57-0.67 and 0.65, 95% CI 0.58-0.72, which was not statistically significantly different to the Metroticket and HALT-HCC scores. The LiTES-HCC score was able to discriminate patients based on post-transplant survival among those meeting Milan and UCSF criteria.
conclusionWe developed and validated a risk score to predict post-transplant survival for patients with HCC. By including HCC- and non-HCC-related variables (e.g., age, chronic kidney disease), this score could allow transplant professionals to prioritize patients with HCC in terms of predicted survival. In the future, this score could be integrated into survival benefit-based models to lead to meaningful improvements in life-years at the population level. LAY SUMMARY: We created a risk score to predict how long patients with liver cancer will live if they get a liver transplant. In the future, this could be used to decide which waitlisted patients should get the next transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.